| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 101 | Simplified Structural Mimetics of AIPS as Quorum Sensing Inhibitors | US17823053 | 2022-08-29 | US20230094587A1 | 2023-03-30 | Helen BLACKWELL; Joseph VASQUEZ; Yiftah TAL GAN |
| Compounds that regulate quorum sensing in Staphylococcal bacteria and in particular in Staphylococcus aureus are provided. Compounds provided are racemic, non-racemic or substantially enantiomerically pure cyclic peptides of formula I: or salts or solvates thereof, where variables R, W, X1, X2, and Z and are as described in the specification and L1 is a divalent linker which contains 1-12 carbon atoms, optionally 1-4 oxygen atoms, optionally one or two carbon-carbon double bonds, and hydrogen atoms to satisfy valency. Certain dimers of the cyclic peptides are also provided. One or more cylic peptides or dimers thereof herein can be employed to inhibit QS and to thus inhibit virulence in Staphylococcus bacteria. Compounds herein and pharmaceutical compositions containing one or more of these compounds are useful in treating infections of Staphylococcus bacteria. Methods for treating such bacterial infections are also provided. | ||||||
| 102 | GAS5 binding compounds, formulations, and uses thereof | US16063077 | 2016-12-15 | US11278521B2 | 2022-03-22 | Niketa A. Patel; Jianfeng Cai |
| Provided herein are compounds that can bind GAS5 long non-coding RNA, compositions thereof, and uses thereof. | ||||||
| 103 | Anthracene-based organic dyes and preparation methods thereof | US16088710 | 2017-05-08 | US10563064B2 | 2020-02-18 | Peng Wang; Yameng Ren; Min Zhang; Junting Wang; Yang Li |
| The invention provides an anthracene-based organic dye and a preparation method thereof. The organic dye provided by the invention has a structure of formula (I) or formula (II), wherein Ra, Rb, and R2-1 to R2-4 are as defined herein. The organic dye provided by the invention is obtained by modifying an anthracene with Ra and Rb or modifying anthracene-based groups decorated with an aryl group or a heteroaryl group with Ra and Rb, thereby the power conversion efficiency of a dye sensitized solar cell is significantly improved when the organic dye prepared according to the present invention is applied in a dye-sensitized solar cell. Furthermore, the preparation method of the organic dye according to the present invention is quite simple together with abundant raw materials and low cost, making it possible to be commercialized. | ||||||
| 104 | Catalysts | US15327806 | 2015-07-22 | US10556988B2 | 2020-02-11 | Andy Chapman; Anthony Chartoire; James Leeland; Michael Kember; Louis Adriaenssens |
| The present invention relates to the field of polymerisation catalysts, and systems comprising said catalysts for polymerising carbon dioxide and an epoxide, a lactide and/or lactone, and/or an epoxide and an anhydride. The catalyst is of formula (I): Wherein M1 and M2 are independently selected from Zn(II), Cr(II), Co(II), Cu(II), Mn(II), Ni(II), Mg(II), Fe(II), Ti(II), V(II), Cr(III)-X, Co(III)-X, Ni(III)-X, Mn(III)-X, Fe(III)-X, Ca(II), Ge(II), Al(III)-X, Ti(III)-X, V(III)-X, Ge(IV)-(X)2 or Ti(IV)-(X)2. R3A is different from R3B; and/or at least one occurrence of E3, E4, E5 and E6 is different to a remaining occurrence of E3, E4, E5 and E6. A ligand, a process of asymmetric N-substitution of a symmetrical ligand and a process for the reaction of: (i) carbon dioxide with an epoxide; (ii) an epoxide and an anhydride; and/or (iii) a lactide and/or a lactone, in the presence of a catalyst is also described. | ||||||
| 105 | Modulators of indoleamine 2,3-dioxygenase | US15759600 | 2016-09-22 | US10472336B2 | 2019-11-12 | Pek Yoke Chong; Martha Alicia De La Rosa; Hamilton D. Dickson; Wieslaw Mieczyslaw Kazmierski; Vicente Samano; Vincent Wing-Fai Tai |
| Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of HIV; including the prevention of the progression of AIDS and general immunosuppression. | ||||||
| 106 | CATALYSTS | US16014079 | 2018-06-21 | US20190055352A1 | 2019-02-21 | Colin Keyworth; Andy Chapman; Anthony Chartoire; Emmalina Hollis; Charlotte Williams; Michael Kember |
| The present invention relates to the field of polymerisation catalysts, and systems comprising these catalysts for polymerising carbon dioxide and an epoxide, a lactide and/or lactone, and/or an epoxide and an anhydride. The catalyst is of formula (I): wherein at least one of M1 or M2 is selected from Ni(II) and Ni(III)-X. A process for the reaction of carbon dioxide with an epoxide; an epoxide and an anhydride; and/or a lactide and/or a lactone in the presence of the catalyst is also described. | ||||||
| 107 | Cyclic carbodiimide compound, polyester film, back sheet for solar cell module, and solar cell module | US14539689 | 2014-11-12 | US09716189B2 | 2017-07-25 | Seiya Sakurai; Makoto Fukuda |
| A polyester film including a cyclic carbodiimide compound represented by the following Formula (O-1) has good film thickness uniformity without increase in viscosity. R1 and R5 represent an alkyl group, an aryl group, or an alkoxy group; R2 to R4 and R6 to R8 represent a hydrogen atom, an alkyl group, an aryl group, or an alkoxy group; X1 and X2 represent a single bond, —O—, —CO—, —S—, —SO2—, —NH—, or —CH2—; and L1 represents a divalent linking group. | ||||||
| 108 | Synthesis of syrbactin proteasome inhibitors | US14981857 | 2015-12-28 | US09359309B2 | 2016-06-07 | Michael C. Pirrung |
| The disclosure relates generally to methods for the preparation of a family of natural compounds, the syrbactins and their analogs. | ||||||
| 109 | Coating compositions | US13871332 | 2013-04-26 | US09146467B2 | 2015-09-29 | Francis Houlihan; Lin Zhang; Alberto Dioses; Meng Li |
| Developable bottom antireflective coating compositions are provided. | ||||||
| 110 | Method for recovering precious metal from solution containing precious metal ions, extracting agent or adsorbent used therefor, and back-extracting agent or desorbent | US13976591 | 2011-12-28 | US09074264B2 | 2015-07-07 | Yukinori Sudo; Takashi Sakaki |
| To provide a method for recovering a precious metal from a solution containing precious metal ions, an extracting agent or adsorbent used therefor, and a back-extracting agent or desorbent.An extracting agent or adsorbent in which precious metal ions are extracted or adsorbed, is brought into contact with a back-extracting agent or desorbent containing a sulfur-containing amino acid derivative represented by the following formula (I): wherein R1 is a methyl group, an ethyl group, a vinyl group, a C3-8 linear, branched or cyclic hydrocarbon group, or a C6-14 aromatic hydrocarbon group, R2's are each independently a hydrogen atom, a methyl group, an ethyl group, a vinyl group, a C3-8 linear, branched or cyclic hydrocarbon group or a C6-14 aromatic hydrocarbon group, and n is 0 or 1, to obtain a solution containing the precious metal ions, which is subjected to a reduction treatment to obtain a precious metal. | ||||||
| 111 | Material for forming resist protective film and method for forming resist pattern using same | US11659006 | 2005-07-29 | US07951523B2 | 2011-05-31 | Keita Ishizuka; Kotaro Endo; Tomovuki Hiranoa |
| In the liquid immersion lithography process, by simultaneously preventing deterioration of a resist film and deterioration of an immersion liquid employed during liquid immersion lithography which uses various immersion liquids, including water, resistance to post exposure delay of the resist film can be improved without increasing the number of processes, thereby making it possible to form a high resolution resist pattern using liquid immersion lithography. Using an alkaline soluble polymer, a crosslinking agent, and a solvent capable of dissolving them as at least constituent component, a composition is prepared and a protective film is formed on the surface of the resist film to be used, using the composition. | ||||||
| 112 | Process for preparation of inclusion compounds between a non-steroidal anti-inflammatory drug and betacyclodextrin by microwave treatment | US10499338 | 2002-12-17 | US07935685B2 | 2011-05-03 | Ferdinando Giordano; Ruggero Bettini |
| A process for the preparation of inclusion complexes of a drug (piroxicam or ibuprofen) and a cyclodextrin, characterised in that: a) the drug and cyclodextrin, in the form of finely divided powders, are mixed in the presence of aqueous or hydroalcoholic solutions, ammonia solutions or acid solutions; b) the resulting mixture is treated in a microwave oven; c) the resulting product is dried under vacuum at room temperature or with heating. | ||||||
| 113 | Anti-infective agents | US10699513 | 2003-10-31 | US07902203B2 | 2011-03-08 | John K. Pratt; David A. Betebenner; Pamela L. Donner; Brian E. Green; Dale J. Kempf; Keith F. McDaniel; Clarence J. Maring; Vincent S. Stoll; Rong Zhang; Hui-Ju Chen; William J. Flosi; Larry L. Klein; Allan C. Krueger; Dachun Liu; Darold L. Madigan; Laura M. Maymon; Todd W. Rockway; Kent D. Stewart; Ming C. Yeung; Qinghua Xie |
| The present invention provides an HCV polymerase inhibiting compound having the formula (I) and a composition comprising a therapeutically effective amount of said compound. The present invention also provides a method for inhibiting hepatitis C virus (HCV) polymerase, a method for inhibiting HCV viral replication, and a method for treating or preventing HCV infection. Processes for making said compounds, and synthetic intermediates employed in said processes, are also provided. | ||||||
| 114 | MACROCYCLIC METAL COMPLEXES FOR THEIR USE AS ANTICANCER AGENTS | US11917660 | 2006-06-14 | US20110039815A1 | 2011-02-17 | Wiley J. Youngs; Claire A. Tessier; Doug A. Medvetz; Michael J. Taschner |
| In one embodiment the present invention relates to a method of treating cancerous cells in a mammal comprising the steps of administering to the cancerous cells an effective amount of a cyclic amine wherein the cyclic amine contains sulfur or nitrogen and the structure includes an interchealted metal ion. | ||||||
| 115 | Aminoamides as orexin antagonists | US12037975 | 2008-02-27 | US07829563B2 | 2010-11-09 | Luca Gobbi; Henner Knust; Parichehr Malherbe; Matthias Nettekoven; Emmanuel Pinard; Olivier Roche; Mark Rogers-Evans |
| The present invention relates to compounds of formula I wherein Ar1, Ar2, Ar3, n, and R1 to R8 are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. These compounds are orexin receptor antagonists and may be useful in the treatment of disorders, in which orexin pathways are involved, like sleep disorders. | ||||||
| 116 | Organic Compounds and their uses | US12527787 | 2008-02-19 | US20100240638A1 | 2010-09-23 | Shawn D. Britt; Jiping Fu; David Thomas Parker; Michiael Patane; Parkash Raman; Branko Radetich; Mohindra Seepersaud; Aregahegn Yifru; Rui Zheng; Trixi Brand; Sylvain Cottens; Claus Ehrhardt; Stefan Andreas Randl; Pascal Rigollier; Nikolaus Schiering; Oliver Simic |
| The present application describes macrocyclic compounds of formula (I) with NS3 protease inhibitory activity for treating hepatitis C virus infection. | ||||||
| 117 | Paclitaxel enhancer compounds | US12009641 | 2008-01-18 | US07671092B2 | 2010-03-02 | Keizo Koya; Lijun Sun; Shoujun Chen; Noriaki Tatsuta; Yaming Wu; Mitsunori Ono |
| Disclosed is a compound represented by the Structural Formula (I): Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R5-R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R7 and R8 are each independently —H, an aliphatic or substituted aliphatic group, or R7 is —H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is ═O or ═S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent.Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with Paclitaxel or an analog of Paclitaxel. | ||||||
| 118 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS | US12474318 | 2009-05-29 | US20100022499A1 | 2010-01-28 | Chaim Gilon |
| Heterocyclic compounds having a relatively flexible backbone are used to create combinatorial libraries that permit screening for lead compounds and selection of drug candidates for a variety of uses in human and veterinary medicine as well as in agriculture. The compounds of the library generally differ in ring size and chirality of substituents on the ring. Also disclosed are methods for providing and screening these libraries, preferably in an automated or computerizable manner, such as by using a computer program to virtually screen the compounds in order to identify those that are predicted to have bioactive conformations that should give rise to desirable biological effects. | ||||||
| 119 | SPATIALLY-DEFINED MACROCYCLES INCORPORATING PEPTIDE BOND SURROGATES | US12471978 | 2009-05-26 | US20090312540A1 | 2009-12-17 | Pierre Deslongchamps; Yves Dory; Luc Ouellet; Gerald Villeneuve; Mahesh Ramaseshan; Daniel Fortin; Mark L. Peterson; Hamid R. Hoveyda; Sylvie Beaubien; Eric Marsault; Graeme L. Fraser |
| Novel spatially-defined macrocyclic compounds incorporating peptide bond surrogates are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target, in particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor. | ||||||
| 120 | 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives | US11605005 | 2006-11-28 | US07538101B2 | 2009-05-26 | Matthias Nettekoven; Jean-Marc Plancher; Hans Richter; Olivier Roche; Rosa Maria Rodriguez Sarmiento; Sven Taylor |
| The present invention relates to compounds of formula I wherein R1, R2 and G are as defined in the description and claims and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors. | ||||||
QQ群二维码
意见反馈
意见反馈